TMEM229A: A Potential Drug Target and Biomarker (G730130)

Target Name: TMEM229A

NCBI ID: G730130

TMEM229A

Other Name(s): T229A_HUMAN | Transmembrane protein 229A | transmembrane protein 229A

TMEM229A: A Potential Drug Target and Biomarker

TMEM229A, also known as T229A_HUMAN, is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the transmembrane protein family and is characterized by the presence of a transmembrane domain and an intracellular loop. TMEM229A has been identified as a potential drug target and biomarker due to its unique structure and the involvement of several diseases, including neurodegenerative disorders, epilepsy, and liver cancer.

TMEM229A is involved in several physiological processes in the body, including cell signaling, neurotransmitter release, and inflammation. It has been shown to play a role in the regulation of ion channels, which are critical for the flow of electrical signals in neurons. TMEM229A has been shown to interact with several intracellular signaling pathways, including the TGF-β pathway, the PDGF pathway, and the NF-kappa-B pathway.

In neurodegenerative disorders, TMEM229A has been shown to be involved in the development and progression of several disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that individuals with these disorders have reduced levels of TMEM229A in their brain tissue compared to healthy individuals. Additionally, experiments have shown that targeting TMEM229A with drugs can improve neurofunction and slow the progression of these disorders.

In addition to its involvement in neurodegenerative disorders, TMEM229A has also been shown to be involved in the development and progression of epilepsy, liver cancer, and other diseases. For example, studies have shown that individuals with epilepsy have lower levels of TMEM229A in their brain tissue compared to healthy individuals, and that targeting TMEM229A with drugs can improve seizure control. Similarly, TMEM229A has been shown to be involved in the development and progression of liver cancer, and targeting it with drugs has been shown to be effective in inhibiting cancer growth.

The unique structure of TMEM229A makes it an attractive drug target. Its transmembrane domain and intracellular loop provide several potential binding sites for small molecules, making it a promising target for drug developers. Additionally, TMEM229A's involvement in several physiological processes in the body makes it a versatile target, as drugs can be developed to target its activity in any of these processes.

In conclusion, TMEM229A is a protein that has been identified as a potential drug target and biomarker. Its unique structure and involvement in several physiological processes make it an attractive target for drug developers. Further research is needed to fully understand the role of TMEM229A in the development and progression of neurodegenerative disorders, epilepsy, liver cancer, and other diseases.

Protein Name: Transmembrane Protein 229A

The "TMEM229A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM229A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets